Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Akebia Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Akebia Therapeutics, Inc.’s stock price such as:

• Akebia Therapeutics, Inc.’s current stock price and volume
• Why Akebia Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for AKBA from analysts
• AKBA’s stock price momentum as measured by its relative strength

About Akebia Therapeutics, Inc. (AKBA)

Before we jump into Akebia Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Want to learn more about Akebia Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Akebia Therapeutics, Inc..

Akebia Therapeutics, Inc.’s Stock Price as of Market Close

As of May 08, 2026, 10:31 AM, CST, Akebia Therapeutics, Inc.’s stock price was $1.155.

Akebia Therapeutics, Inc. is down 2.12% from its previous closing price of $1.180.

During the last market session, Akebia Therapeutics, Inc.’s stock traded between $1.140 and $1.200. Currently, there are approximately 267.05 million shares outstanding for Akebia Therapeutics, Inc..

Akebia Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Akebia Therapeutics, Inc. Stock Price History

Akebia Therapeutics, Inc.’s (AKBA) price is currently down 16.3% so far this month.

During the month of May, Akebia Therapeutics, Inc.’s stock price has reached a high of $1.540 and a low of $1.130.

Over the last year, Akebia Therapeutics, Inc. has hit prices as high as $4.079 and as low as $1.130. Year to date, Akebia Therapeutics, Inc.’s stock is down 28.26%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Akebia Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of May 07, 2026,, no analysts have changed their rating of Akebia Therapeutics, Inc.’s stock over the last month.

Additionally, you'll want to evaluate Akebia Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Akebia Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Akebia Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Akebia Therapeutics, Inc. (AKBA) by visiting AAII Stock Evaluator.

Relative Price Strength of Akebia Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 07, 2026, Akebia Therapeutics, Inc. has a weighted four-quarter relative price strength of -20.20%, which translates to a Momentum Score of 10 and is considered to be Very Weak.

Want to learn more about how Akebia Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Akebia Therapeutics, Inc. Stock Price: Bottom Line

As of May 8, 2026, Akebia Therapeutics, Inc.’s stock price is $1.155, which is down 2.12% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Akebia Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.